<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231002059592N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-17</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of dexamethasone administration on the progress of labor in pregnant women referred to Hospital  .</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of dexamethasone administration on the progress of labor in pregnant women referred to hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73053</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Other, Purpose: Health service research, Randomization description: simple block (patients are divided into four blocks equally between the intervention and control groups, then each block is given numerical tag codes, and finally, random numbers are selected from among the determined numbers using a random table and according to the determined blocks People are assigned to two groups, Blinding description: This study is double blind. In this way, pregnant women along with midwives who carry out drug orders are completely unaware. In this regard, sealed envelopes are used to allocate interventions.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Investigating the effect of dexamethasone administration on the progress of labor in pregnant women referred to Ba'ath Sanandaj Hospital in 1402.</hc_freetext>
      <i_freetext>First, NST to evaluate fetal heart rate and TOCO to check uterine contractions as well as preliminary tests are taken from pregnant mothers. All patients undergo vaginal examination by the researcher and their urine and cervical dilatation scores are recorded. Then the demographic and clinical information of the patients including age, BMI, gestational age and sex of the fetus will be collected based on the checklist (Appendix 1). The mother's vital signs including heart rate, blood pressure, breathing rate and body temperature are checked and recorded in the medical record. After determining cervical dilatation, pregnant mothers are divided into 4 groups including two control groups, one latent phase group and one active phase group based on random blocks of 4. 1) Mothers in the latent phase control group who have dilation below 5 cm are treated with routine pregnancy induction drugs (misoprostol manufactured by Samisaz company 50 micrograms orally every 3 to 6 hours and normal saline 2 cc intravenously) and are subjected to vaginal examinations in the course of labor. When the mother enters the active phase, based on uterine contractions in the case of hypotonia, treated with intravenous oxytocin (half a milliunit per minute - manufactured by Caspian Company - until optimal uterine contractions are reached Mothers in the control group with the active phase, if they have a dilatation of more than 6 cm, if necessary (in case of hypotonia), are treated with intravenous oxytocin (according to the protocol mentioned above) and intravenous normal saline. 2 cc is placed until the desired uterine contractions are reached for delivery. 2) Pregnant mothers in the latent phase group are treated with intravenous dexamethasone at a dose of 8 mg (manufactured by Kimia Daru Company) and routine labor induction drugs (misoprostol orally 50 micrograms each 3 to 6 hours or EASI) until they reach the active phase, after entering the active phase, in case of hypotonia, they are treated with intravenous oxytocin (according to the protocol mentioned above) until they reach the optimal uterine contractions for delivery. take 3) Pregnant mothers in the active FAR group, who were initially treated with misoprostol or mechanical method, and who have reached 5-6 cm dilation, are treated with intravenous dexamethasone at a dose of 8 mg (manufactured by Kimia Daru Company) and, if necessary, oxytocin. IV is placed (according to the protocol mentioned above) until optimal uterine contractions are reached for delivery. It should be noted that during the course of labor, the mother's vital signs will be regularly checked by medical personnel according to the protocol and recorded in the file. In the event of any possible side effect or threat to the health of the mother and fetus, the treatment process is stopped and necessary measures are taken depending on the condition of the mother. During the study, the following outcomes will be evaluated, and after the birth of the baby, the baby's weight will be measured with a scale and recorded in the checklist (Appendix 1)..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It will be shared if the subject is approved and effective and has no side effects</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>sonia ranjbar badrloo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>besat hospital.sanandaj</address>
        <city>كردستان</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6619667761</zip>
        <telephone>+98 87 3328 5914</telephone>
        <email>dr.ranjbar3134@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>sonia ranjbar barloo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>besat hospital.sanandaj</address>
        <city>sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6619667761</zip>
        <telephone>+98 87 3328 5914</telephone>
        <email>dr.ranjbar3134@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Term(37 w)
nuli par
cephalic</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>multi parati
rupther of membran
cpd(cephalopelvic disproportion)
Iugr(intrauterin growth restrition)
oligohydroaminus
fetal distres</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First, NST to evaluate fetal heart rate and TOCO to check uterine contractions as well as preliminary tests are taken from pregnant mothers. All patients undergo vaginal examination by the researcher and their urine and cervical dilatation scores are recorded. Then the demographic and clinical information of the patients including age, BMI, gestational age and sex of the fetus will be collected based on the checklist (Appendix 1). The mother's vital signs including heart rate, blood pressure, breathing rate and body temperature are checked and recorded in the medical record. After determining cervical dilatation, pregnant mothers are divided into 4 groups including two control groups, one latent phase group and one active phase group based on random blocks of 4. 1) Mothers in the latent phase control group who have dilation below 5 cm are treated with routine pregnancy induction drugs (misoprostol manufactured by Samisaz company 50 micrograms orally every 3 to 6 hours and normal saline 2 cc intravenously) and are subjected to vaginal examinations in the course of labor. When the mother enters the active phase, based on uterine contractions in the case of hypotonia, treated with intravenous oxytocin (half a milliunit per minute - manufactured by Caspian Company - until optimal uterine contractions are reached Mothers in the control group with the active phase, if they have a dilatation of more than 6 cm, if necessary (in case of hypotonia), are treated with intravenous oxytocin (according to the protocol mentioned above) and intravenous normal saline. 2 cc is placed until the desired uterine contractions are reached for delivery. 2) Pregnant mothers in the latent phase group are treated with intravenous dexamethasone at a dose of 8 mg (manufactured by Kimia Daru Company) and routine labor induction drugs (misoprostol orally 50 micrograms each 3 to 6 hours or EASI) until they reach the active phase, after entering the active phase, in case of hypotonia, they are treated with intravenous oxytocin (according to the protocol mentioned above) until they reach the optimal uterine contractions for delivery. take 3) Pregnant mothers in the active FAR group, who were initially treated with misoprostol or mechanical method, and who have reached 5-6 cm dilation, are treated with intravenous dexamethasone at a dose of 8 mg (manufactured by Kimia Daru Company) and, if necessary, oxytocin. IV is placed (according to the protocol mentioned above) until optimal uterine contractions are reached for delivery. It should be noted that during the course of labor, the mother's vital signs will be regularly checked by medical personnel according to the protocol and recorded in the file. In the event of any possible side effect or threat to the health of the mother and fetus, the treatment process is stopped and necessary measures are taken depending on the condition of the mother. During the study, the following outcomes will be evaluated, and after the birth of the baby, the baby's weight will be measured with a scale and recorded in the checklist (Appendix 1).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Primary outcomes:1. The average number of received oxytocin units (measurements: during the entire active phase - variable measurement method: dropper and the number of oxytocin drops included in the medical record)2. The average number of misoprostol pills received (measurements: in the entire latent phase - how to measure based on the number of pills taken in the medical record)3. The average time interval between the latent phase and the start of the active phase of labor (measurement period: from the beginning of induction until reaching 5 to 6 cm dilatation - variable measurement method: vaginal examination)4. The average duration of the active phase of labor (measurement period: from dilation of 5 to 6 cm until dilation reaches 10 cm - method of variable measurement: vaginal examination)5. The average rate of cervical dilation (measurement interval: the rate of progress of cervical dilation every one hour from the start of induction to the dilation of 10 cm - how to measure the variable: partograph)6. The average duration of the second stage of labor (measurement period: from dilation of 10 cm to the complete exit of the fetus-variable measurement method: partograph)7. The average time interval between the beginning of induction of labor and the birth of the baby (measurement period: from the beginning of induction to the complete removal of the placenta and fetus-variable method of measurement: partograph)8. The average time interval of spontaneous rupture of the water bag. Timepoint: The time interval between birth according to the registry data until the time of entering the studyBy measuring the height and weight of the studied women and the result of dividing the weight by the square of the height in kilograms per square meterBased on the first ultrasound of the first trimester, the fetus contains FHRBaby weight at birth using a baby scale in gramsThe gender of the baby is girl or boyThe advance score is the scoring of the pregnant mother's vaginal examination to determine the type of treatment during childbirth. In this, scoring 5 parameters including 1) cervical dilatation 2) relaxation 3) station4) Consistency 5) The position of the cervix is given 0, 1, 2 and 3 points and then the total score of each mother before delivery is calculated.The amount and dose of oxytocin used is for the labor induction process.The amount and dose of misoprostol taken.The time interval between the beginning of induction of labor and the beginning of the active phase of labor (dilation of the cervix 5 to 6 cm) isThe time interval between dilation of 5 to 6 cm and dilatation of 10 cm of the cervixThe rate of progression of cervical dilation every hour from the start of induction to the dilatation of 10 cm of the cervix.The time interval between dilatation of 10 cm and complete expulsion of the fetusThe time interval between the start of induction and the complete expulsion of the placenta and fetusThe causes of cesarean delivery include fetal heart failure, severe vaginal bleeding, endangering the life of the mother and fetus, descent or dilatation.The Apgar scale is a quick and reliable way to assess the health status of a newborn baby.Hospitalization of newborns after birth in the neonatal intensive care unitAny adverse medical event that is temporarily associated with the use of a medicinal product, safety and tolerability are evaluated based on the incidence of adverse events.1. Control group: pregnant mothers in this group receive oxytocin or misoprostol2. Latent phase group: pregnant mothers in this group receive intravenous dexamethasone and misoprostol.3. Active phase group: pregnant mothers in this group receive intravenous dexamethasone and oxytocin.Determining the time of mother's water sac rupture automatically. Method of measurement: According to the information completed by the person in the questionnaireAccording to the information completed by the person in the questionnaireUltrasound evaluation of the first trimesterAccording to the information completed by the person in the questionnaireAccording to the information completed by the person in the questionnaireEvaluation based on vaginal examination by a gynecologist/patient with a pre-test score of 6 or more receives oxytocin and a patient with a urine score of less than 6 receives misoprostolIt is calculated according to the injection amount by medical personnel.It is calculated according to the amount used by medical personnel.Evaluation using partograph and vaginal examinationEvaluation using partograph and vaginal examinationUsing a partographUsing a partographUsing a partographFollow-up and follow-up of the pregnant mother by a gynecologistFive simple criteria include appearance, pulse, crying, agile movements, and breathing pattern, each of which is numbered from zero to two, and after summarizing the overall health of the baby, it is determined.Newborn visit by gynecologistFollow-up and follow-up of the pregnant mother by a gynecologistBased on random allocationUsing a partograph.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Secondary consequences:1. The frequency of cesarean delivery and its causes (measurement period: from the beginning of induction to the end of the study (throughout the study) - variable measurement method: being monitored by a gynecologist throughout the study)2. Neonatal outcomes including the average Apgar score of the first minute and the fifth minute (measuring periods: the first and fifth minutes after the birth of the baby - variable measurement method: it includes five components: 1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is scored 0, 1, or 2).3. The frequency of hospitalization of newborns in the intensive care unit (measurement periods: after the birth of the baby - variable measurement method: newborn visits by gynecologists). Timepoint: The time interval between birth according to the registry data until the time of entering the studyBy measuring the height and weight of the studied women and the result of dividing the weight by the square of the height in kilograms per square meterBased on the first ultrasound of the first trimester, the fetus contains FHRBaby weight at birth using a baby scale in gramsThe gender of the baby is girl or boyThe advance score is the scoring of the pregnant mother's vaginal examination to determine the type of treatment during childbirth. In this, scoring 5 parameters including 1) cervical dilatation 2) relaxation 3) station4) Consistency 5) The position of the cervix is given 0, 1, 2 and 3 points and then the total score of each mother before delivery is calculated.The amount and dose of oxytocin used is for the labor induction process.The amount and dose of misoprostol taken.The time interval between the beginning of induction of labor and the beginning of the active phase of labor (dilation of the cervix 5 to 6 cm) isThe time interval between dilation of 5 to 6 cm and dilatation of 10 cm of the cervixThe rate of progression of cervical dilation every hour from the start of induction to the dilatation of 10 cm of the cervix.The time interval between dilatation of 10 cm and complete expulsion of the fetusThe time interval between the start of induction and the complete expulsion of the placenta and fetusThe causes of cesarean delivery include fetal heart failure, severe vaginal bleeding, endangering the life of the mother and fetus, descent or dilatation.The Apgar scale is a quick and reliable way to assess the health status of a newborn baby.Hospitalization of newborns after birth in the neonatal intensive care unitAny adverse medical event that is temporarily associated with the use of a medicinal product, safety and tolerability are evaluated based on the incidence of adverse events.1. Control group: pregnant mothers in this group receive oxytocin or misoprostol2. Latent phase group: pregnant mothers in this group receive intravenous dexamethasone and misoprostol.3. Active phase group: pregnant mothers in this group receive intravenous dexamethasone and oxytocin.Determining the time of mother's water sac rupture automatically. Method of measurement: According to the information completed by the person in the questionnaireAccording to the information completed by the person in the questionnaireUltrasound evaluation of the first trimesterAccording to the information completed by the person in the questionnaireAccording to the information completed by the person in the questionnaireEvaluation based on vaginal examination by a gynecologist/patient with a pre-test score of 6 or more receives oxytocin and a patient with a urine score of less than 6 receives misoprostolIt is calculated according to the injection amount by medical personnel.It is calculated according to the amount used by medical personnel.Evaluation using partograph and vaginal examinationEvaluation using partograph and vaginal examinationUsing a partographUsing a partographUsing a partographFollow-up and follow-up of the pregnant mother by a gynecologistFive simple criteria include appearance, pulse, crying, agile movements, and breathing pattern, each of which is numbered from zero to two, and after summarizing the overall health of the baby, it is determined.Newborn visit by gynecologistFollow-up and follow-up of the pregnant mother by a gynecologistBased on random allocationUsing a partograph.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sanandaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-14</approval_date>
        <contact_name>Ethics Committee of Kurdistan University of Medical Sciences</contact_name>
        <contact_address>besat hospital Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
